G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
February 28, 2024 06:30 ET
|
G1 Therapeutics
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
February 27, 2024 08:30 ET
|
G1 Therapeutics
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024
February 15, 2024 08:30 ET
|
G1 Therapeutics
G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee
February 12, 2024 16:05 ET
|
G1 Therapeutics
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent DMC
G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024 06:45 ET
|
G1 Therapeutics
G1 Therapeutics provides Corporate and Clinical Update at the 42md Annual J.P. Morgan healthcare conference.
G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 09:00 ET
|
G1 Therapeutics
G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 02, 2024 16:51 ET
|
G1 Therapeutics
January 2024 Inducement Grants
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
December 05, 2023 09:26 ET
|
G1 Therapeutics
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent
G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium
November 29, 2023 20:37 ET
|
G1 Therapeutics
New data at the 2023 SABCS explore the long-term impact of trilaciclib on survival outcomes in patients with metastatic TNBC